单体治疗学“MNPR-101-Zr 阶段1”试验表明,在各种癌症类型中,有针对肿瘤的有效目标。 Monopar Therapeutics' MNPR-101-Zr Phase 1 trial demonstrates effective tumor targeting in various cancer types.

Monopar Therapeutics 报告了其 MNPR-101-Zr 1 期临床试验令人鼓舞的早期结果，证实了其在各种癌症类型中靶向表达尿激酶纤溶酶原激活剂受体 （uPAR） 的肿瘤的能力。 Monopar Therapeutics has reported encouraging early results from its MNPR-101-Zr Phase 1 clinical trial, confirming its ability to target tumors expressing the urokinase plasminogen activator receptor (uPAR) in various cancer types. 试验表明,与标准成像方法相比,MNPR-101-Zr有效地在转移肿瘤中地方化。 The trial showed that MNPR-101-Zr effectively localized in metastatic tumors compared to standard imaging methods. 在此公告发布后，Monopar 的股价大幅飙升，该公司计划在今年晚些时候推出一项新的治疗试验。 Following this announcement, Monopar's stock surged significantly, and the company plans to launch a new therapeutic trial later this year.